Lab Asset and Facility Management in Pharma Summit Europe Hilton London Olympia, London

Not only has the pandemic fuelled life science investment, but it has also made us realise the importance of seamless R and D operations and lab facility requirements. Over the last 2 years we have seen huge investments into expanding R and D infrastructure within Europe; including a new £500m new biocluster in Canary Wharf in London, Velo3D opening a new European technical centre in Germany and the LabConnect announcement of increasing their footprint in Europe.

Amidst these investments and expansion plans in the LS sector, Lab Operations, R and D Asset and Facility leaders in biopharma are playing an increasingly vital role to ensure internal capabilities and external supplier management are fit-for-purpose to support their scientific teams and R and D pipeline progression.